SUVN 911

Drug Profile

SUVN 911

Alternative Names: SUVN911

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Antidepressants
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 16 Jul 2018 Suven Life Sciences Limited completes a phase I trial in Major depressive disorder (In volunteers) in USA (PO) (NCT03551288)
  • 22 May 2018 Phase-I clinical trials in Major depressive disorder (In volunteers) in USA (PO) (NCT03551288)
  • 14 Mar 2018 Suven Life Sciences completes a phase I trial in Major depressive disorder (In volunteers) in USA (PO) (NCT03155503)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top